FDA Explores How To Reduce Sodium Levels In The Food Supply

Today’s average sodium intake is several times what the body requires and its long-term effect on our health is very serious. Hypertension, or high blood pressure, affects one in three U.S. adults – nearly 75 million people aged 20 or older. An additional 50 million adults suffer from pre-hypertension. High blood pressure can increase the risk for heart attacks, strokes, heart failure, and kidney failure. Too much sodium in the daily diet is a major contributor to high blood pressure.

A new report from the Institute of Medicine (IOM) concludes that national action is imperative to reduce the sodium content of foods if we are to make significant progress toward reducing the risk of hypertension and major cardiovascular events for Americans.

The FDA will more thoroughly review the recommendations of the IOM report and build plans for how the FDA can continue to work with other federal agencies, public health and consumer groups, and the food industry to support the reduction of sodium levels in the food supply. The Department of Health and Human Services (DHHS) will be establishing an interagency working group on sodium at the Department that will review options and next steps.

I'm pleased to see these efforts. In our household, we don't add salt, and do our best to avoid processed foods, and foods containing way too much sodium salt.

Reference:  FDA Issues Statement on IOM Sodium Report
Consumer Information:  Lowering Salt in Your Diet

Return Home: http://drughealth.blogspot.com/

FDA Webinar on FDA Inspection Process

When:     Thursday, March 25, 2010, at 2 p.m. ET

Where:    https://collaboration.fda.gov/inspectionprocess/

Host:       FDA’s Office of Regulatory Affairs (ORA), 301-827-3101

             ORAContactUs@FDA.HHS.GOV

Speaker: Michael C. Rogers, deputy director, Office of Regional Operations

To ensure the safety of marketed products, FDA experts inspect domestic and foreign establishments, check shipments of imported products, and collect and test product samples for signs of contamination.

During this webinar, FDA experts will present information on

• the organization within FDA that is charged with conducting inspections
• the facilities FDA is responsible for inspecting
• what an inspection involves
• inspection follow-up and enforcement actions
• the rigorous training that inspectors receive

The presentation will run approximately 30 minutes and will include an opportunity to ask questions.

To join the webinar:

1. Click https://collaboration.fda.gov/inspectionprocess/ (or cut and paste it into your Internet browser)
2. Click "Enter as a Guest," fill in your name, then click "Enter Room"
3. Dial 1-877-685-5350 and enter participant passcode: 969082

You might also be interested in:

Surviving an FDA Inspection - a training course by SkillsPlus International Inc.

This class prepares plant personnel to participate in an FDA Inspection.

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog
SkillsPlus Intl Inc. - GMP Compliance Training Experts
SkillsPlus Intl Info Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store 

HHS Updates HIV Treatment Guidelines (free pdf)

Updated March 20, 2023

Get the most recent guidelines:
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV - US Dept of HHS

- - -  the original post follows below - - -

A Department of Health and Human Services (HHS) panel has recommended two drug regimens be added to the list of preferred protease-inhibitor components in revised guidelines on the use of antiretrovirals in HIV-1-infected patients. The panel just published their revised guidelines, "
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. These guidelines are intended to help providers make decisions about the use of antiretroviral agents.

It should be noted that these guidelines generally represent the state of knowledge regarding the use of antiretroviral agents. However, as the science rapidly evolves, the availability of new agents and new clinical data may rapidly change therapeutic options and preferences. The guidelines, therefore, are updated frequently by the Panel.

Return Home: http://drughealth.blogspot.com/